These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30177490)

  • 21. Pathophysiology underlying drooling in Parkinson's disease: oropharyngeal bradykinesia.
    Karakoc M; Yon MI; Cakmakli GY; Ulusoy EK; Gulunay A; Oztekin N; Ak F
    Neurol Sci; 2016 Dec; 37(12):1987-1991. PubMed ID: 27613712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
    Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Csikós J; Cairney CJ; Blitzer A
    Neurology; 2019 Apr; 92(17):e1982-e1991. PubMed ID: 30918101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
    Sheffield JK; Jankovic J
    Expert Rev Neurother; 2007 Jun; 7(6):637-47. PubMed ID: 17563247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SIALORRHEA AND XEROSTOMIA IN PARKINSON'S DISEASE PATIENTS.
    Špiljak B; Lisak M; Pašić H; Trkanjec Z; Lovrenčić Huzjan A; Bašić Kes V
    Acta Clin Croat; 2022 Aug; 61(2):320-326. PubMed ID: 36818932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.
    Petracca M; Guidubaldi A; Ricciardi L; Ialongo T; Del Grande A; Mulas D; Di Stasio E; Bentivoglio AR
    Toxicon; 2015 Dec; 107(Pt A):129-40. PubMed ID: 26327120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Digestive disorders in Parkinson's disease: dysphagia and sialorrhea].
    González-Fernández J; Prieto-Albin R; Velasco-Palacios L; Jorge-Roldán S; Cubo-Delgado E
    Rev Neurol; 2010 Feb; 50 Suppl 2():S51-4. PubMed ID: 20205142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?
    Nóbrega AC; Rodrigues B; Torres AC; Enzo A; Melo A
    J Neurol Sci; 2007 Feb; 253(1-2):85-7. PubMed ID: 17229441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of sialorrhea in Parkinson's disease patients with clonidine. Double-blind, comparative study with placebo].
    Serrano-Dueñas M
    Neurologia; 2003; 18(1):2-6. PubMed ID: 12590375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort.
    Perez-Lloret S; Nègre-Pagès L; Ojero-Senard A; Damier P; Destée A; Tison F; Merello M; Rascol O;
    Eur J Neurol; 2012 Jan; 19(1):28-37. PubMed ID: 21453441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum toxin in the treatment of sialorrhea.
    Svetel M; Vasić M; Dragasević N; Pekmezović T; Petrović I; Kostić V
    Vojnosanit Pregl; 2009 Jan; 66(1):9-12. PubMed ID: 19195257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.
    Mancini F; Zangaglia R; Cristina S; Sommaruga MG; Martignoni E; Nappi G; Pacchetti C
    Mov Disord; 2003 Jun; 18(6):685-8. PubMed ID: 12784273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drooling rating scales in Parkinson's disease: A systematic review.
    Nascimento D; Carmona J; Mestre T; Ferreira JJ; Guimarães I
    Parkinsonism Relat Disord; 2021 Oct; 91():173-180. PubMed ID: 34583888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy?
    Santamato A; Panza F; Solfrizzi V; Frisardi V; Ranieri M; Fiore P
    J Rehabil Med; 2008 Nov; 40(10):882-3. PubMed ID: 19242630
    [No Abstract]   [Full Text] [Related]  

  • 35. The Effect of Glycopyrrolate on Nocturnal Sialorrhea in Patients Using Clozapine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial.
    Man WH; Colen-de Koning JC; Schulte PF; Cahn W; van Haelst IM; Doodeman HJ; Egberts TC; Heerdink ER; Wilting I
    J Clin Psychopharmacol; 2017 Apr; 37(2):155-161. PubMed ID: 28129312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excessive buccal saliva in patients with Parkinson's disease of the French COPARK cohort.
    Rascol O; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Fabbri M; Meissner WG; Rachdi A; Tison F; Perez-Lloret S;
    J Neural Transm (Vienna); 2020 Dec; 127(12):1607-1617. PubMed ID: 32880023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drooling, Swallowing Difficulties and Health Related Quality of Life in Parkinson's Disease Patients.
    Arboleda-Montealegre GY; Cano-de-la-Cuerda R; Fernández-de-Las-Peñas C; Sanchez-Camarero C; Ortega-Santiago R
    Int J Environ Res Public Health; 2021 Jul; 18(15):. PubMed ID: 34360429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease.
    Bruno V; Freitas ME; Mancini D; Lui JP; Miyasaki J; Fox SH
    Can J Neurol Sci; 2018 Jan; 45(1):23-29. PubMed ID: 29334040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease.
    Dogu O; Apaydin D; Sevim S; Talas DU; Aral M
    Clin Neurol Neurosurg; 2004 Mar; 106(2):93-6. PubMed ID: 15003297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.